Northern Trust Corp Cure Vac N.V. Transaction History

Northern Trust Corp

$586 Billion
Q2 2024

A detailed history of Northern Trust Corp transactions in Cure Vac N.V. stock. As of the latest transaction made, Northern Trust Corp holds 31,615 shares of CVAC stock, worth $95,477. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,615

Previous 35,815 11.73%

Holding current value

$95,477

Previous $108,000 0.93%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.31 - $4.99 $9,702 - $20,958	-4,200 Reduced 11.73%	31,615 $107,000
Q1 2024 May 14, 2024	SELL	$2.94 - $4.34 $24,522 - $36,199	-8,341 Reduced 18.89%	35,815 $108,000
Q4 2023 Feb 13, 2024	BUY	$3.96 - $6.41 $174,857 - $283,039	44,156 New	44,156 $185,000
Q2 2023 Aug 11, 2023	BUY	$6.69 - $12.25 $6,649 - $12,176	994 Added 1.19%	84,688 $882,000
Q1 2023 May 15, 2023	SELL	$6.38 - $12.5 $7,439 - $14,575	-1,166 Reduced 1.37%	83,694 $583,000
Q4 2022 Feb 13, 2023	SELL	$5.75 - $8.5 $7,498 - $11,084	-1,304 Reduced 1.51%	84,860 $511,000
Q3 2022 Nov 14, 2022	BUY	$7.48 - $15.24 $644,506 - $1.31 Million	86,164 New	86,164 $679,000
Q2 2022 Aug 12, 2022	SELL	$13.18 - $19.41 $1.49 Million - $2.19 Million	-112,749 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$14.73 - $35.25 $82,311 - $196,977	5,588 Added 5.21%	112,749 $2.21 Million
Q4 2021 Feb 08, 2022	SELL	$33.72 - $48.22 $61,775 - $88,339	-1,832 Reduced 1.68%	107,161 $3.68 Million
Q3 2021 Nov 15, 2021	SELL	$49.26 - $74.5 $1.77 Million - $2.68 Million	-36,021 Reduced 24.84%	108,993 $5.95 Million
Q2 2021 Aug 13, 2021	BUY	$56.91 - $127.53 $8.25 Million - $18.5 Million	145,014 New	145,014 $10.7 Million

Others Institutions Holding CVAC

# of Institutions

Shares Held

14.4M

Call Options Held

241K

Put Options Held

419K

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $566M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Cure Vac N.V. Transaction History